Qiming Venture Partners and Four Portfolio Companies Named to PharmCube TOP15 Annual Awards
The awards aim to establish benchmark investment institutions and enterprises with annual bellwether significance for China's pharmaceutical industry.
At the recently held 2025 PMC Pharmaceutical Investment and Financing Conference and the 3rd PharmaCube TOP15 Awards Ceremony, the China Innovative Drug Venture Capital Institutions TOP15, China Innovative Drug Emerging Enterprises TOP15, and China Innovative Drug Business Development TOP15 lists were unveiled. The selections aim to establish benchmark institutions and companies with annual风向标 significance for China's pharmaceutical industry.
Qiming Venture Partners was named to the China Innovative Drug Venture Capital Institutions TOP15 list.
Qiming Venture Partners
Named to
China Innovative Drug Venture Capital Institutions TOP15
Qiming portfolio company Ze'an Biopharmaceutical was named to the China Innovative Drug Emerging Enterprises TOP15 list, while LaNova Medicines, MediLink Therapeutics, and Allorion Therapeutics were named to the China Innovative Drug Business Development TOP15 list.
Ze'an Biopharmaceutical
Named to
China Innovative Drug Emerging Enterprises TOP15
LaNova Medicines, MediLink Therapeutics, Allorion Therapeutics
Named to
China Innovative Drug Business Development TOP15
- 2024 China Innovative Drug Venture Capital Institutions TOP15
PharmaCube based its selection on investment activity in 2024, with emphasis on early-stage and lead investment events. Against the backdrop of deep adjustment in the industry's investment and financing ecosystem, venture capital institutions in 2024 are reconstructing the paradigm of biopharmaceutical investment with strategic vision. PharmaCube hopes to express encouragement for the listed institutions through data and rankings.
- 2024 China Innovative Drug Emerging Enterprises TOP15
Based on big data in the pharmaceutical industry, PharmaCube evaluated global innovative drug companies across dimensions including innovation capability and R&D progress, applying different weights to calculate comprehensive scores. Listed companies were founded within the past five years, are at early funding stages of Series A or earlier, and raised new funding in 2024 of RMB 100 million or more.
- 2024 China Innovative Drug Business Development TOP15
Based on 2024 transaction events involving Chinese pharmaceutical companies, particularly in the innovative drug space, PharmaCube evaluated and weighted multiple factors including transaction value, number of deals, project value, and partnership structure to compile this list.
Source | PharmaCube
Past Coverage
Qiming Honors | Qiming Venture Partners and Portfolio Companies Named to 2nd PharmaCube TOP15 Annual Awards Qiming Honors | Qiming Venture Partners and Portfolio Companies Win VBData 2024 Future Healthcare Equity Investment Awards Qiming Perspectives | Qiming Venture Partners' Kan Chen: Outlook on China's Pharmaceutical Innovation and Investment in a Globalized Competitive Environment
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management of $9.5 billion. Since its inception, the firm has focused on investing in outstanding early- and growth-stage companies in the Technology and Consumer (T&C) and Healthcare sectors.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have gone public on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. More than 80 portfolio companies have become recognized unicorns or super-unicorns.
Many Qiming portfolio companies have grown into the most influential players in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), UBTECH (09880.HK), WeRide (NASDAQ:WRD), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Berry Genomics (000710.SZ), SinoCellTech (688520.SH), Yuanxin Technology, ClinChoice, Belief BioMed, Biren Technology, and others.